Mastrangelo Mj
Impact in
-
- Immunotherapy and Immune Responses
-
- CAR-T cell therapy research
- Cutaneous Melanoma Detection and Management
- Cancer Immunotherapy and Biomarkers
Papers in
- Oncology 13
- Cutaneous Melanoma Detection and Management 5
- Cancer Immunotherapy and Biomarkers 4
- CAR-T cell therapy research 2
-
- Immunotherapy and Immune Responses 6
- Immune Cell Function and Interaction 2
- Co-authors
- David Berd (6 shared papers)Harris Dt (1 shared paper)Henry C. Maguire Jr. (1 shared paper)Magüire Hc (2 shared papers)Takahiko Sato (1 shared paper)Shields Cl (1 shared paper)Shoei‐Sheng Lee (1 shared paper)Edward Francis McClay (1 shared paper)
- Journals
- PubMed (21 papers)
- Partner nations
- United States
In The Last Decade
Mastrangelo Mj
21 papers receiving 454 citations
Peers
Comparison fields: 5 of 67
- Immunology 200
- Oncology 231
- Ophthalmology 66
- Biotechnology 30
- Hematology 32
Countries citing papers authored by Mastrangelo Mj
This map shows the geographic impact of Mastrangelo Mj's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mastrangelo Mj with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mastrangelo Mj more than expected).
Fields of papers citing papers by Mastrangelo Mj
This network shows the impact of papers produced by Mastrangelo Mj. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mastrangelo Mj. The network helps show where Mastrangelo Mj may publish in the future.
Co-authors
The 13 scholars most cited alongside Mastrangelo Mj, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 21 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Clinical and immunological significance of human melanoma cytotoxic antibody. | 1975 | 70 |
| 2 | BOLD+interferon in the treatment of metastatic uveal melanoma: first report of active systemic therapy. | 1997 | 68 |
| 3 | Systemic chemotherapy for metastatic melanoma. | 1988 | 46 |
| 4 | Bacillus Calmette-Guerin in the treatment of neoplastic disease. | 1974 | 37 |
| 5 | The immunoaugmenting effects of cancer chemotherapeutic agents. | 1986 | 37 |
| 6 | Immunotherapy of melanoma with intralesional BCG. | 1973 | 36 |
| 7 | In situ cytokine gene transfection using vaccinia virus vectors. | 1996 | 33 |
| 8 | Randomized prospective trial of DTIC (NSC-45388) alone versus BCNU (NSC-409962) plus vincristine (NSC-67574) in the treatment of metastatic malignant melanoma. | 1976 | 30 |
| 9 | Theory and application of early systemic therapy. | 1991 | 30 |
| 10 | Active specific immunization in the treatment of patients with melanoma. | 1996 | 23 |
| 11 | Clinical trial with subcutaneously administered 5-azacytidine (NSC-102816). | 1974 | 22 |
| 12 | Allergy-induced hepatic toxicity associated with dacarbazine. | 1987 | 22 |
| 13 | Phase II study of ICRF-159 in patients with metastatic colorectal carcinoma previously exposed to systemic chemotherapy. | 1976 | 17 |
| 14 | Current condition and prognosis of tumor immunotherapy: a second opinion. | 1984 | 17 |
| 15 | Positive phase II trial of dibromodulcitol in patients with metastatic melanoma refractory to DTIC and a nitrosourea. | 1978 | 11 |
| 16 | Phase II trial of VM-26 in patients with metastatic malignant melanoma. | 1978 | 8 |
| 17 | Phase II study of adriamycin (NSC-123127) in patients with metastatic melanoma. | 1976 | 7 |
| 18 | Assessment of survival rates with metastatic malignant melanomas. | 1986 | 6 |
| 19 | Phase I study of ICRF-159 (NSC-129943) in human solid tumors. | 1973 | 5 |
| 20 | Adjuvant therapy for cutaneous melanoma. | 1995 | 4 |
About Mastrangelo Mj
Mastrangelo Mj is a scholar working on Oncology, Immunology, Molecular Biology, Biotechnology and Radiology, Nuclear Medicine and Imaging, having authored 21 papers that have together received 531 indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (6 papers), Melanoma and MAPK Pathways (6 papers), Cutaneous Melanoma Detection and Management (5 papers), Cancer Immunotherapy and Biomarkers (4 papers), Cancer Research and Treatments (2 papers), Immune Cell Function and Interaction (2 papers), CAR-T cell therapy research (2 papers) and Monoclonal and Polyclonal Antibodies Research (2 papers). The work is most often cited by research in Immunology (200 citations), Oncology (231 citations), Ophthalmology (66 citations), Biotechnology (30 citations) and Hematology (32 citations). Mastrangelo Mj has collaborated with scholars based in United States. Frequent co-authors include David Berd, Harris Dt, Henry C. Maguire Jr., Magüire Hc, Takahiko Sato, Shields Cl, Shoei‐Sheng Lee, Edward Francis McClay, Darwin O. Chee and Tetsuo Satō. Their work appears in journals such as PubMed.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.